Elanco Animal Health Inc (NYSE:ELAN) shares traded 26.29% higher at $12.01 on Wall Street last session.
ELAN stock price is now 20.34% away from the 50-day moving average and -2.36% away from the 200-day moving average. The market capitalization of the company currently stands at $5.96B.
With the price target of $18, UBS recently initiated with Buy rating for Elanco Animal Health Inc (NYSE: ELAN). On December 02, 2024, Leerink Partners recently initiated its ‘Market Perform’ rating on the stock quoting a target price of $14, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Kurzius Lawrence Erik, Director bought 10,000 shares of the company’s stock on Mar 07 ’25. The stock was bought for $109,000 at an average price of $10.90. Upon completion of the transaction, the Director now directly owns 101,459 shares in the company, valued at $1.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’25, Director Kurzius Lawrence Erik bought 10,000 shares of the business’s stock. A total of $102,000 was incurred on buying the stock at an average price of $10.20. This leaves the insider owning 111,459 shares of the company worth $1.34 million. A total of 0.95% of the company’s stock is owned by insiders.
During the past 12 months, Elanco Animal Health Inc has had a low of $8.02 and a high of $18.80. As of last week, the company has a debt-to-equity ratio of 0.73, a current ratio of 2.44, and a quick ratio of 1.25.
The net profit margin was 7.61% and return on equity was 5.49% for ELAN. The company reported revenue of $1.02 billion for the quarter, compared to $1.03 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.45 percent. For the current quarter, analysts expect ELAN to generate $1.18B in revenue.
